PARP1 and breast cancer: Phenanthridine-derived PARP inhibitors possess a promising potency to arrest proliferation (G2/M arrest) and cause cell death in MCF-7 and MDA231 human breast cancer cells, without impairing normal proliferating human epithelial cells, fibroblasts, or quiescent cells (neurons, cardiomyocytes).